Though initial tests did not include younger age groups, Pfizer-BioNTech eventually started a smaller trial with around 1,000 12-15 year-olds enrolled. More participants will be enlisted after this group has received its second dose, and all data will be released once the analysis is complete.
In the meantime, in February 2021, Israel announced the  Pfizer-BioNTech would be made available to people aged 16 and over.